Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 434Carcinoma, Non-Small-Cell Lung 360Neoplasms 339Prostatic Neoplasms 276Colorectal Neoplasms 264Multiple Myeloma 206Lung Neoplasms 195Neoplasm Metastasis 179Leukemia, Myeloid, Acute 160Ovarian Neoplasms 155Pancreatic Neoplasms 152Squamous Cell Carcinoma of Head and Neck 138Melanoma 126Recurrence 104Head and Neck Neoplasms 99Glioblastoma 99Carcinoma, Renal Cell 98Endometrial Neoplasms 96Carcinoma, Hepatocellular 93Lymphoma, Non-Hodgkin 92Precursor Cell Lymphoblastic Leukemia-Lymphoma 91Lymphoma 91Triple Negative Breast Neoplasms 90Stomach Neoplasms 88Uterine Cervical Neoplasms 85Brain Neoplasms 85Lymphoma, Large B-Cell, Diffuse 80Urinary Bladder Neoplasms 77Glioma 74Leukemia, Lymphocytic, Chronic, B-Cell 73

Interventions

cabozantinib 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Urachal adenocarcinoma × 30 days × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡